About Immusoft

Immusoft is a Seattle-based biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP™) technology were developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft.

Immusoft’s ISP™ in vitro proof-of-concept studies were the first in the world to demonstrate a clinically viable method for directly programming a patient’s immune cells to produce broadly neutralizing antibodies against HIV. These studies showed efficient transduction and differentiation of circulating human B cells into fully differentiated plasma cells, producing specific HIV antibodies. Other potential therapeutic applications of ISP™ technology include: enzyme replacement, autoimmune disorders, neurodegenerative disorders, infectious diseases, and maintenance therapy for cancers.

The first ISP™-based treatment Immusoft will advance to human trials is a therapy for MPS I, a rare, genetic, lysosomal storage disease. ISP™ technology will be used to make patient's immune cells continually secrete α-L-iduronidase (IDUA).

Our proof-of-concept studies were carried out in collaboration with Seattle BioMed and Caltech. We are currently collaborating with the Fred Hutchinson Cancer Research Center on a STTR grant application to generate pre-clinical data for our HIV therapeutic.

Contact

For general inquiries, please contact info@immusoft.com. Immusoft is lead by:

• Chief Executive Officer, Matthew Scholz

• Chief Science Officer, Eric Herbig

• Vice President of Business Development, Zach Hall